Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Today, February 12, 2024, is the first day of the subscription period in Qlife Holding AB's ("Qlife" or the "Company") issue of a maximum of 215,187,249 units, corresponding to a maximum of 4,949,306,727 shares and 3,442,995,984 warrants series TO 4 and TO 5 with preferential rights for existing shareholders at a subscription price of SEK 0.23 per unit, corresponding to 0.01 per share (the "Rights Issue").
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE
Summary of the Rights IssueOne (1) existing share entitles to one (1) unit right and three (3) unit rights entitle the holder to subscribe for one (1) unit in the Company. Each unit consists of twenty-three (23) new shares, eight (8) warrants series TO 4, and eight (8) warrants series TO 5.
The Rights Issue comprises a maximum of 215,187,249 units, corresponding to a maximum of 4,949,306,727 shares and 3,442,995,984 warrants series TO 4 and TO 5. Upon full subscription in the Rights Issue, Qlife will initially receive approximately SEK 49.5 million before deduction of issue costs. In the event that all warrants series TO 4 and TO 5 issued in the Rights Issue are exercised for subscription of shares, the Company will receive additional issue proceeds of approximately SEK 73.2 million before deduction of issue costs.
One (1) warrant series TO 4 entitles the holder to subscribe for one (1) new share in the Company during the period 7 - 21 June 2024 at an exercise price of SEK 0.02 per share, and one (1) warrant series TO 5 entitles the holder to subscribe for one (1) new share in the Company during the period 21 November - 5 December 2024 at an exercise price of SEK 0.0225 per share.
The subscription price in the Rights Issue is SEK 0.23 per unit, corresponding to SEK 0.01 per share. The warrants are issued free of charge.
The subscription period in the Rights Issue runs between 12 - 26 February 2024.
Warrants series TO 4 and TO 5 are expected to be admitted to trading on Nasdaq First North Growth Market in close connection with the registration of the Rights Issue with the Swedish Companies Registration Office and the conversion of BTU to shares and warrants.
The Rights Issue is covered by guarantee commitments up to approximately 61 percent. The guarantee commitments consist partly of a so-called top guarantee and partly of a so-called bottom guarantee.
In order to secure the Company's liquidity needs until the Rights Issue has been completed, the Company has raised a bridge loan of SEK 5.0 million from Formue Nord Markedsneutral A/S.
For further information on the Rights Issue, please refer to the published Prospectus.
Prospectus and subscription notes
The EU Growth Prospectus that was published by the Company on February 9, 2024, containing complete terms and conditions (the "Prospectus"), is available on the Company's website (https://qlifeholding.com/en/rights-issue-2024) and on Eminova Fondkommission's website (www.eminova.se). Subscription notes are available on the Company's and Eminova Fondkommission's respective websites.
Timeline for the Rights Issue
12 - 26 February Subscription period
2024
13 - 21 February Trading in unit rights
2024
13 February 2024 Trading in BTUs
until the Rights
Issue is registered
with the Swedish
Companies
Registration Office
28 February 2024 Expected announcement of the outcome in the Rights Issue
Advisors
Eminova Partners Corporate Finance AB and Gemstone Capital A/S act as financial advisors, and Eminova Fondkommission AB has been appointed as issuing agent, in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal advisor to Qlife.
This information was provided by the contact person above for publication on 12 February 2024, at 17:40 CET.